Working to provide information, support and access to established, new or innovative treatments for Atrial Fibrillation (AF)
Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE)
Atrial fibrillation (AF) is the most common cardiac arrhythmia, occurring in 1–2% of the general population. Its prevalence varies between continents and ethnicity, but the estimated number of patients with AF worldwide might be between 30 and 100 million.1 This prevalence is expected to increase significantly in the next 30–50 years due to an ageing population, and increasing risk factors to develop AF, including arterial hypertension and diabetes.2–5 In all populations studied, both prevalence and incidence are higher in men than in women and increase with age.6
WORLD HEART RHYTHM WEEK 5-11 JUNE 2017 TAKE THE PULSE CHECK CHALLENGE – IT COULD SAVE YOUR LIFE
HIGH RISK AF PATIENTS DENIED ACCESS TO LIFE-SAVING TREATMENT
New patient survey results show 80% of AF patients say ‘YES’ to the freedom that INR self-monitoring gives them
The purpose of this survey was to help discover patient thoughts and opinions about INR self-monitoring versus clinic visits. Several trials have demonstrated that patient self-monitoring (PSM) by those on long term warfarin significantly improves time in therapeutic range (TTR) and leads to better management outcomes.
Arrhythmia Alliance places 3000th Public Access Defibrillator on World Restart the Heart Day
“AEDs must be as commonplace as fire extinguishers and smoke alarms if we are to dramatically reduce the number of deaths from sudden cardiac arrest in the UK.”
New real-world analysis reports lower risk of major bleeding with dabigatran compared to rivaroxaban in stroke prevention
Ingelheim, Germany, 13.October 2016 – A large observational study by researchers from the U.S. FDA has found that dabigatran (150 mg twice daily) was associated with lower rates of intracranial haemorrhage and major extracranial bleeding, including major gastrointestinal bleeding than rivaroxaban (20 mg once daily) in patients with atrial fibrillation (AF). The study is the largest observational study to-date comparing the two drugs, and analysed data from over 118,000 AF patients. Based on the data published in JAMA Internal Medicine, the accompanying Editor’s Note written by Parks and Redberg suggests that physicians should “prescribe dabigatran over rivaroxaban for patients with atrial fibrillation.”
HEART RHYTHM CONGRESS DEBATES NEED FOR SCREENING OF UNKNOWN OR UNDIAGNOSED ATRIAL FIBRILLATION (AF)
Thursday 13 October, Heart Rhythm Congress, Birmingham, UK: Many of the world’s leading authorities on the management and treatment of atrial fibrillation (AF) met at the Heart Rhythm Congress to debate the latest evidence supporting the value of screening for people with unknown AF.
UK’S LEADING HEART RHYTHM CHARITY AND CARDIAC SPECIALISTS CALL FOR AN URGENT RETHINK BY NHS ENGLAND ON ITS PILOT TECHNOLOGY EVALUATION PROCESS
Thursday 13 October: Birmingham, UK: Arrhythmia Alliance, the UK’s leading heart rhythm charity, and many of the UK’s leading cardiac specialists are calling on NHS England to reconsider its ‘Commissioning through Evaluation’ process, which as of next month will leave hundreds of AF (Atrial Fibrillation) patients at serious risk of suffering a debilitating AF-related stroke.
International Heart Rhythm Congress Calls For Urgent Action To Prevent Thousands of Unnecessary Deaths From Arrhythmias
Thursday 29 September, World Heart Day, Birmingham, UK: Over 3,000 heart rhythm experts and healthcare professionals from around the world will converge on the ICC, Birmingham, for the annual Heart Rhythm Congress (HRC), 9-12 October, the UK's largest educational congress devoted solely to heart rhythm disorders.